# Opioid Induced Constipation Drug Market

> Opioid Induced Constipation Drug Market Research Report By Opioid Type (Agonists, Partial Agonists, Mixed Agonists/Antagonists, Antagonists), By Drug Class (Peripherally Acting -Opioid Receptor Antagonists, Peripherally Acting Non-Opioid Receptor Agonists, Centrally Acting Laxatives, Osmotic Laxatives), By Route of Administration (Oral, Rectal, Intravenous), By Indication (Opioid-Induced Constipation, Non-Opioid-Induced Constipation) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.18%
- **2024:** $ 1.9 Billion
- **2025:** $ 2 Billion
- **2035:** $ 3.31 Billion
- **Key Players:** Boehringer Ingelheim (DE), Takeda Pharmaceutical Company Limited (JP), AstraZeneca(GB), Mallinckrodt Pharmaceuticals (IE), Pfizer Inc. (US), Sorrento Therapeutics (US), Salix Pharmaceuticals (US), NantKwest (US)

**Report ID:** MRFR/HC/32071-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/opioid-induced-constipation-drug-market-33909

---

## Market Summary

## **Opioid Induced Constipation Drug Market Overview**

As per MRFR analysis, the Opioid Induced Constipation Drug Market Size was estimated at 1.90 (USD Billion) in 2024. The Opioid Induced Constipation Drug Market Industry is expected to grow from 2.00 (USD Billion) in 2025 to 3.14 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.18% during the forecast period (2025 - 2034).

### **Key Opioid Induced Constipation Drug Market Trends Highlighted**

The Opioid Induced Constipation Drug market exhibits promising growth prospects, driven by several key factors. The increasing prevalence of opioid-induced constipation, coupled with the growing awareness of its debilitating effects, is a major driver. Additionally, the introduction of novel drug formulations and the expansion of patient access to these therapies are fueling market growth.

A competitive environment with established players and emerging companies characterizes the market landscape. Key market drivers include the rise in opioid use, technological advancements, and the expansion of healthcare infrastructure in emerging markets. Opportunities for growth are present in the development and commercialization of new drug formulations, personalized treatment approaches, and the integration of digital health technologies.

Recent trends in the Opioid Induced Constipation Drug market include the growing adoption of non-opioid therapies, such as laxatives and enemas. The shift towards patient-centric care and the integration of telemedicine services are also shaping market dynamics. Furthermore, the increasing focus on reducing opioid misuse and addiction is likely to drive the development of safer and more effective constipation management strategies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Opioid Induced Constipation Drug Market Drivers**

### **Rising Prevalence of Opioid-Induced Constipation (OIC)**

Opioid-induced constipation (OIC) is a common and debilitating side effect of opioid use, affecting up to 90% of patients. The increasing prevalence of opioid use, particularly for chronic pain management, is driving the demand for effective OIC treatments. The Opioid Induced Constipation Drug Market Industry is expected to witness significant growth as a result of this growing patient population.

### **Increasing Awareness and Recognition of OIC**

Historically, OIC has been under-recognized and undertreated. However, growing awareness among healthcare professionals and patients about the impact of OIC on quality of life is leading to increased diagnosis and treatment. This increased recognition is contributing to the growth of the Opioid Induced Constipation Drug Market Industry.

### **Development of Novel and More Effective Therapies**

Ongoing research and development efforts are resulting in the introduction of novel and more effective OIC treatments. These new therapies offer improved efficacy, reduced side effects, and more convenient administration, making them more appealing to patients and healthcare providers. The availability of these innovative treatments is expected to drive further the growth of the Opioid Induced Constipation Drug Market Industry.

## **Opioid Induced Constipation Drug Market Segment Insights:**

### **Opioid Induced Constipation Drug Market Opioid Type Insights  **

The Opioid Induced Constipation Drug Market is segmented by Opioid Type into Agonists, Partial Agonists, Mixed Agonists/Antagonists, and Antagonists. Among these, Agonists held the largest market share in 2023, accounting for over 45% of the global revenue. This dominance is attributed to the widespread use of opioids, such as morphine and oxycodone, in pain management, which often leads to constipation as a side effect. Agonists work by binding to opioid receptors in the gut, reducing the propulsive movements of the intestines and causing constipation.

The market for Agonists is expected to continue growing steadily in the coming years, driven by the rising prevalence of chronic pain conditions and the increasing use of opioids for pain relief. Partial Agonists, which have both agonist and antagonist properties, accounted for a significant share of the market in 2023 and are projected to maintain a steady growth rate in the coming years. Partial Agonists are often used to manage pain while minimizing the constipating side effects associated with full agonists.

Mixed Agonists/Antagonists, which have both agonist and antagonist effects at different opioid receptors, have a smaller market share compared to Agonists and Partial Agonists.

However, their unique mechanism of action, which allows for pain relief with reduced constipation, is expected to drive their market growth in the coming years. Antagonists, which block the effects of opioids at opioid receptors, accounted for the smallest market share in 2023. Antagonists are primarily used to reverse the effects of opioid overdose and are not typically prescribed for the treatment of opioid-induced constipation. The market for Antagonists is expected to remain relatively small in the coming years, with limited growth potential.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Opioid Induced Constipation Drug Market Drug Class Insights **

The Opioid Induced Constipation Drug Market segmentation by Drug Class, such as Peripherally Acting Opioid Receptor Antagonists, Peripherally Acting Non-Opioid Receptor Agonists, Centrally Acting Laxatives, and Osmotic Laxatives, allows for a comprehensive analysis of the market landscape. Among these segments, Peripherally Acting Opioid Receptor Antagonists emerged as the dominant category, capturing approximately 60% of the Opioid Induced Constipation Drug Market revenue in 2023. The widespread adoption of drugs like naloxegol and methylnaltrexone, which effectively counteract opioid-induced constipation without affecting analgesia, has contributed to this segment's growth.

The remaining market share is divided among Peripherally Acting Non-Opioid Receptor Agonists (25%), Centrally Acting Laxatives (10%), and Osmotic Laxatives (5%). These segments offer alternative treatment options for patients experiencing constipation due to opioid use. As the prevalence of opioid-induced constipation continues to rise, the demand for effective treatment options is expected to drive the growth of the Opioid Induced Constipation Drug Market in the coming years.

### **Opioid Induced Constipation Drug Market Route of Administration Insights **

The Opioid Induced Constipation Drug Market is segmented by Route of Administration into Oral, Rectal, and Intravenous. Among these, the Oral segment held the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of this segment can be attributed to the ease of administration, patient convenience, and cost-effectiveness of oral medications.

The Rectal segment is expected to witness a steady growth rate during the forecast period, owing to the increasing adoption of rectal suppositories and enemas for the management of opioid-induced constipation in patients who are unable to tolerate oral mucositis medications.

The Intravenous segment is anticipated to account for a smaller market share compared to the Oral and Rectal segments. However, it is expected to exhibit a significant growth rate during the forecast period, primarily due to the increasing use of intravenous medications in hospitalized patients with severe opioid-induced constipation.

### **Opioid Induced Constipation Drug Market Indication Insights **

The Global Opioid-Induced Constipation Drug Market is segmented by Indication into Opioid-Induced Constipation and Non-Opioid-Induced Constipation. The Opioid-Induced Constipation segment accounted for a larger share of the market in 2023 and is projected to continue to dominate the market throughout the forecast period. This is due to the increasing prevalence of opioid-induced constipation, which is a common side effect of opioid use.

The Non-Opioid-Induced Constipation segment is also expected to witness significant growth over the forecast period due to the rising incidence of non-opioid-induced constipation, which a variety of factors such as dehydration, certain medications and underlying medical conditions can cause.

### **Opioid Induced Constipation Drug Market Regional Insights **

The Opioid Induced Constipation Drug Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 (0.782 USD Billion) and is expected to maintain its dominance throughout the forecast period (1.185 USD Billion). The high prevalence of opioid-induced constipation in the region, coupled with the availability of advanced healthcare infrastructure and a large patient population, contribute to the significant market size. Europe is another major market for opioid-induced constipation drugs, with a substantial patient population and a well-established healthcare system (0.299 USD Billion in 2023, 0.476 USD Billion in 2032).

The APAC region is expected to witness the fastest growth during the forecast period, owing to the rising incidence of opioid-induced constipation and the increasing adoption of opioid-induced constipation drugs in countries like China and India (0.345 USD Billion in 2023, 0.564 USD Billion in 2032). South America and MEA also represent significant markets for opioid-induced constipation drugs, with a growing patient population and a rising demand for effective treatments (South America: 0.192 USD Billion in 2023, 0.322 USD Billion in 2032; MEA: 0.092 USD Billion in 2023, 0.153 USD Billion in 2032).

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Opioid Induced Constipation Drug Market Key Players And Competitive Insights:**

Major players in Opioid Induced Constipation Drug Market industry strive to maintain a competitive edge by investing in research and development (R&D) of novel products and technologies. They engage in mergers and acquisitions to expand their product portfolios and gain access to new markets. Leading Opioid Induced Constipation Drug Market players focus on strengthening their distribution channels to increase their reach and improve customer service. The Opioid Induced Constipation Drug Market is characterized by a high level of competition, with several key players vying for market share.

These players implement various strategies to maintain their position and gain an edge over their competitors.

A leading company in the Opioid Induced Constipation Drug Market is Allergan. Allergan is a global pharmaceutical and medical device company that develops, manufactures, and markets a broad portfolio of products. The company offers a range of opioid-induced constipation drugs, such as Linzess (linaclotide) and Movantik (naloxegol). Allergan has a strong presence in key markets around the world and benefits from a wide distribution network. The company invests heavily in R&D, which has resulted in the development of innovative products that meet the evolving needs of patients.

A competitor company in the Opioid Induced Constipation Drug Market is AstraZeneca. AstraZeneca is a multinational pharmaceutical and biopharmaceutical company that specializes in the development and marketing of innovative medicines. The company offers a range of opioid-induced constipation drugs, such as Entereg (alvimopan) and Moventig (naloxegol). AstraZeneca has a strong presence in major markets and a robust pipeline of potential new products. The company focuses on developing therapies that improve patient outcomes and address unmet medical needs.

### **Key Companies in the Opioid Induced Constipation Drug Market Include**

- Salix Pharmaceuticals
- Mallinckrodt
- [AstraZeneca](https://www.astrazeneca.com/media-centre/press-releases/2014/fda-approved-movatnik-opioid-induced-constipation-chronic-non-cancer-pain-patients-16092014.html#!)
- Intec Pharma
- Impel NeuroPharma
- Cosmo Pharmaceuticals
- Xeris Pharmaceuticals
- Synergy Pharmaceuticals
- Purdue Pharma
- Akcea Therapeutics
- Reliant Pharmaceuticals
- Braintree Laboratories
- BioDelivery Sciences International
- Cara Therapeutics

## Opioid Induced Constipation Drug Industry Developments

- **Q2 2024: Bausch Health Announces FDA Approval of New Formulation of RELISTOR® (methylnaltrexone bromide) Tablets for Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain** Bausch Health received FDA approval for a new formulation of RELISTOR® tablets, expanding treatment options for adults suffering from opioid-induced constipation related to chronic non-cancer pain.
- **Q1 2024: Daiichi Sankyo and Takeda Announce Strategic Partnership to Co-Develop and Commercialize Novel Opioid-Induced Constipation Therapy in Japan** Daiichi Sankyo and Takeda entered a strategic partnership to co-develop and commercialize a new therapy targeting opioid-induced constipation, aiming to address unmet needs in the Japanese market.
- **Q2 2024: AstraZeneca Receives European Commission Approval for MOVENTIG® (naloxegol) for Expanded Indication in Opioid-Induced Constipation** AstraZeneca secured European Commission approval for an expanded indication of MOVENTIG® (naloxegol), allowing broader use in patients with opioid-induced constipation across Europe.
- **Q3 2024: BioDelivery Sciences International Appoints New CEO to Lead Expansion in Opioid-Induced Constipation Drug Portfolio** BioDelivery Sciences International appointed a new CEO to drive the company's growth strategy, with a focus on expanding its opioid-induced constipation drug portfolio.
- **Q2 2024: Shionogi Launches New Opioid-Induced Constipation Drug in Japan** Shionogi launched a new prescription drug for opioid-induced constipation in Japan, marking its entry into the growing gastrointestinal therapeutics market.
- **Q1 2025: Salix Pharmaceuticals Opens New Manufacturing Facility to Increase Production of OIC Therapies** Salix Pharmaceuticals opened a new manufacturing facility dedicated to increasing production capacity for its opioid-induced constipation therapies.
- **Q2 2025: Theravance Biopharma Announces Positive Phase 3 Results for TD-1211 in Opioid-Induced Constipation** Theravance Biopharma announced positive Phase 3 clinical trial results for TD-1211, a novel treatment for opioid-induced constipation, supporting future regulatory submissions.
- **Q1 2024: Nektar Therapeutics and Eli Lilly Enter Collaboration to Develop Next-Generation OIC Treatments** Nektar Therapeutics and Eli Lilly formed a collaboration to develop next-generation treatments for opioid-induced constipation, combining their expertise in pain and gastrointestinal disorders.
- **Q3 2024: Pfizer Sells Rights to OIC Drug to Specialty Pharma Firm** Pfizer sold the rights to one of its opioid-induced constipation drugs to a specialty pharmaceutical company, streamlining its portfolio and focusing on core therapeutic areas.
- **Q2 2025: Takeda Secures Regulatory Approval for New OIC Drug in Europe** Takeda received regulatory approval in Europe for a new opioid-induced constipation drug, expanding its gastrointestinal product offerings in the region.
- **Q1 2025: Mallinckrodt Announces $100 Million Investment to Expand OIC Drug Research and Development** Mallinckrodt announced a $100 million investment to expand research and development efforts focused on new therapies for opioid-induced constipation.
- **Q4 2024: Progenics Pharmaceuticals Receives FDA Fast Track Designation for OIC Drug Candidate** Progenics Pharmaceuticals received FDA Fast Track designation for its investigational drug targeting opioid-induced constipation, expediting the development and review process.

## **Opioid Induced Constipation Drug Market Segmentation Insights**

### **Opioid Induced Constipation Drug Market Opioid Type Outlook**

- Agonists
- Partial Agonists
- Mixed Agonists/Antagonists
- Antagonists

### **Opioid Induced Constipation Drug Market Drug Class Outlook**

- Peripherally Acting -Opioid Receptor Antagonists
- Peripherally Acting Non-Opioid Receptor Agonists
- Centrally Acting Laxatives
- Osmotic Laxatives

### **Opioid Induced Constipation Drug Market Route of Administration Outlook**

- Oral
- Rectal
- Intravenous

### **Opioid Induced Constipation Drug Market Indication Outlook**

- Opioid-Induced Constipation
- Non-Opioid-Induced Constipation

### **Opioid Induced Constipation Drug Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa  

## Market Drivers

### Rising Geriatric Population

The increasing geriatric population is a significant factor contributing to the growth of the Opioid Induced Constipation Drug Market. Older adults are more likely to be prescribed opioids for chronic pain conditions, which subsequently raises the risk of developing opioid-induced constipation.
 
Data suggests that the elderly population is projected to reach 1.5 billion by 2050, indicating a substantial market for OIC treatments. As this demographic continues to expand, the demand for effective management of OIC will likely increase, prompting pharmaceutical companies to focus on developing targeted therapies. This demographic shift underscores the importance of addressing OIC in the context of aging populations, thereby driving the Opioid Induced Constipation Drug Market.

### Increasing Prevalence of Opioid Use

The rising prevalence of opioid prescriptions for chronic pain management is a primary driver of the Opioid Induced Constipation Drug Market. As healthcare providers increasingly rely on opioids to treat various conditions, the incidence of opioid-induced constipation (OIC) has escalated. Reports indicate that approximately 40% of patients on chronic opioid therapy experience OIC, leading to a growing need for effective treatment options.
 
This trend suggests that as the number of opioid prescriptions continues to rise, so too will the demand for drugs specifically targeting OIC. Consequently, pharmaceutical companies are likely to invest in research and development to create innovative solutions, thereby expanding the Opioid Induced Constipation Drug Market.

### Regulatory Support for OIC Treatments

Regulatory bodies are increasingly recognizing the need for effective treatments for opioid-induced constipation, which serves as a significant driver for the Opioid Induced Constipation Drug Market. Recent guidelines from health authorities emphasize the importance of addressing OIC as a critical aspect of opioid therapy management.
 
This regulatory support not only encourages the development of new drugs but also facilitates faster approval processes for existing treatments. As a result, pharmaceutical companies are motivated to enhance their product offerings, leading to a more competitive landscape within the Opioid Induced Constipation Drug Market. The potential for increased market access and reimbursement options further bolsters the attractiveness of investing in OIC therapies.

### Growing Awareness Among Healthcare Professionals

There is a notable increase in awareness among healthcare professionals regarding the implications of opioid-induced constipation, which is driving the Opioid Induced Constipation Drug Market. Educational initiatives and training programs are being implemented to inform clinicians about the prevalence and management of OIC. This heightened awareness is likely to result in more proactive screening and treatment of OIC in patients receiving opioid therapy.
 
As healthcare providers become more knowledgeable about the available treatment options, the demand for effective OIC drugs is expected to rise. This trend indicates a shift towards a more comprehensive approach to pain management, thereby enhancing the growth potential of the Opioid Induced Constipation Drug Market.

### Technological Advancements in Drug Delivery Systems

Technological advancements in drug delivery systems are poised to transform the Opioid Induced Constipation Drug Market. Innovations such as sustained-release formulations and targeted delivery mechanisms are enhancing the efficacy and patient compliance of OIC treatments. These advancements not only improve the therapeutic outcomes but also reduce the side effects associated with traditional opioid therapies.
 
As pharmaceutical companies leverage these technologies to develop more effective OIC drugs, the market is likely to witness an influx of novel products. This trend indicates a shift towards more sophisticated treatment options, which could significantly enhance the overall landscape of the Opioid Induced Constipation Drug Market.

## Future Outlook

The Opioid Induced Constipation Drug Market is projected to grow at a 5.18% CAGR from 2025 to 2035, driven by increasing opioid prescriptions and rising awareness of treatment options.

**New opportunities:**

- Development of combination therapies targeting opioid-induced constipation and pain relief. Expansion into [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)platforms for remote patient management and prescription. Investment in patient education programs to enhance adherence to treatment regimens.

By 2035, the market is expected to solidify its position as a critical segment in pain management.

## Segment Insights

### By Opioid Type: Agonists (Largest) vs. Antagonists (Fastest-Growing)

In the Opioid Induced Constipation Drug Market, Agonists hold the largest share due to their established role in treating opioid-induced constipation. This category encompasses potent medications that work by activating opioid receptors, thereby providing effective relief from constipation caused by opioid use. In contrast, Antagonists are rapidly gaining attention, comprising a significant portion of the market driven by their ability to counteract the side effects of opioids. Their increasing acceptance among healthcare providers highlights an essential shift towards balancing pain management and mitigating constipation issues.

Agonists (Dominant) vs. Antagonists (Emerging)

Agonists play a dominant role in the Opioid Induced Constipation Drug Market due to their effectiveness in treating constipation linked to opioid use. These drugs activate specific receptors in the gut to enhance bowel movements, proving crucial for patients undergoing opioid therapies. Emerging Antagonists, however, are quickly carving out a niche by focusing on alleviating the severe side effects associated with opioid consumption.
 
Their unique mechanism of action, which involves blocking opioid receptors in the gut, provides a compelling alternative that is increasingly recognized as a necessary complement to traditional agonist therapies. As awareness increases, the demand for Antagonists is expected to rise, indicating a trend towards more balanced opioid management.

### By Drug Class: Peripherally Acting Opioid Receptor Antagonists (Largest) vs. Peripherally Acting Non-Opioid Receptor Agonists (Fastest-Growing)

The opioid induced constipation drug market is witnessing a diverse distribution of shares across various drug classes. Peripherally acting opioid receptor antagonists (PAMORAs) hold a substantial portion of the market share, attributed to their effectiveness in countering the adverse gastrointestinal effects associated with opioid pain medications. In contrast, peripherally acting non-opioid receptor agonists, though still smaller in share, are emerging rapidly due to their favorable safety profiles and efficacy, capturing the attention of both practitioners and patients alike.
 
Growth trends in this market segment are primarily driven by the increasing prevalence of opioid use across diverse medical conditions, necessitating effective countermeasures against constipation. The drive towards innovative formulations in PAMORAs has solidified their dominant position, while new entrants, particularly in the non-opioid receptor agonist category, are gaining traction. The growing awareness of side effects linked to opioid therapies has led to an uptick in demand for alternatives, positioning non-opioid agonists as the fastest-growing options in this space.

PAMORAs (Dominant) vs. Peripherally Acting Non-Opioid Receptor Agonists (Emerging)

Peripherally acting opioid receptor antagonists (PAMORAs) dominate the opioid induced constipation drug market due to their specific action in alleviating constipation without affecting analgesia. They work by blocking the peripheral opioid receptors, thereby improving bowel function in patients on chronic opioid therapy. Their established efficacy and safety have led to strong recommendations from healthcare providers.
 
On the other hand, peripherally acting non-opioid receptor agonists are emerging as a promising new choice. They provide relief without the complications associated with traditional opioids or PAMORAs. These agents capitalize on a growing market preference for treatments with fewer side effects, and their rapid entry into the marketplace reflects a shift toward more comprehensive management of opioid-induced side effects.

### By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the Opioid Induced Constipation Drug Market, the 'Oral' route of administration occupies the largest market share, owing to its convenience and patient preference. Patients generally favor oral medications as they are easier to administer and manage within their daily routines. 'Intravenous' administration is gaining traction, particularly in clinical settings where quick onset of action is critical, making it the fastest-growing segment in this market.

Oral (Dominant) vs. Intravenous (Emerging)

The 'Oral' route of administration is a dominant choice in the Opioid Induced Constipation Drug Market, characterized by ease of use and a favorable patient experience. Oral formulations are extensively available, making them a go-to solution for managing opioid-related constipation. On the other hand, the 'Intravenous' route represents an emerging trend, especially in hospital settings where rapid relief is required. While its use is less common in outpatient settings due to higher costs and potential complications, its growth is driven by increasing awareness and the need for immediate treatment options in acute cases.

### By Indication: Opioid-Induced Constipation (Largest) vs. Non-Opioid-Induced Constipation (Fastest-Growing)

The Opioid Induced Constipation Drug Market is predominantly driven by the opioid-induced constipation segment, which holds a significant share due to the widespread use of opioids for pain management. This segment is characterized by an increased prevalence of constipation as a side effect of opioid medications, leading to a steady demand for specific treatment options.
 
On the other hand, the non-opioid-induced constipation segment is gradually gaining traction, attributed to factors such as an increase in awareness about various types of constipation and growing treatment options available for non-opioid-related cases.

Opioid-Induced Constipation (Dominant) vs. Non-Opioid-Induced Constipation (Emerging)

The opioid-induced constipation segment is considered the dominant force within the market, largely owing to the significant number of patients undergoing opioid therapy for pain management. This segment necessitates specialized treatments tailored to alleviate the constipation that arises from opioid use, prompting pharmaceutical companies to focus on developing effective solutions.
 
In contrast, the non-opioid-induced constipation segment is emerging as a critical area of interest, fueled by increased patient awareness and a rise in lifestyle-related constipation issues. This segment is witnessing innovative treatment options, expanding its market appeal. As patient education enhances, the demand for both categories is likely to evolve, promoting a more comprehensive understanding of constipation treatment.

## Regional Market Share Analysis

### North America : Leading Market for OIC Drugs

North America is the largest market for Opioid Induced Constipation (OIC) drugs, holding approximately 60% of the global market share. The growth is driven by the high prevalence of opioid prescriptions, increasing awareness of OIC, and supportive regulatory frameworks. The U.S. is the primary contributor, followed by Canada, which is experiencing a rise in demand for effective treatment options due to an aging population and rising opioid use.

The competitive landscape in North America is robust, featuring key players such as Pfizer Inc., Mallinckrodt Pharmaceuticals, and Sorrento Therapeutics. These companies are actively involved in research and development to introduce innovative therapies. The presence of advanced healthcare infrastructure and favorable reimbursement policies further enhances market growth, making it a focal point for OIC drug development.

### Europe : Emerging Market with Potential

Europe is witnessing a significant increase in the demand for Opioid Induced Constipation (OIC) drugs, holding around 25% of the global market share. The growth is fueled by rising opioid prescriptions and a growing awareness of OIC among healthcare professionals. Countries like Germany and the UK are leading this market, supported by regulatory initiatives aimed at improving patient outcomes and access to effective treatments.

The competitive landscape in Europe includes major players such as AstraZeneca and Boehringer Ingelheim, which are focusing on innovative solutions for OIC. The European Medicines Agency (EMA) is actively involved in regulating these drugs, ensuring safety and efficacy. The increasing collaboration between pharmaceutical companies and healthcare providers is expected to drive further growth in this region.

### Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is emerging as a significant market for Opioid Induced Constipation (OIC) drugs, accounting for approximately 10% of the global market share. The growth is driven by increasing opioid use for chronic pain management and a rising awareness of OIC. Countries like Japan and Australia are at the forefront, with supportive healthcare policies and a growing elderly population contributing to market expansion. The competitive landscape is evolving, with local and international players entering the market. Companies such as Takeda Pharmaceutical Company Limited are focusing on developing effective OIC treatments tailored to regional needs. The increasing investment in healthcare infrastructure and research initiatives is expected to further enhance market growth in this region, making it a key area for future opportunities.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa (MEA) region represents an untapped market for Opioid Induced Constipation (OIC) drugs, holding about 5% of the global market share. The growth potential is significant, driven by increasing opioid prescriptions for pain management and a growing awareness of OIC. However, challenges such as regulatory hurdles and limited access to healthcare services hinder market development.

Countries like South Africa and the UAE are beginning to recognize the need for effective OIC treatments. The competitive landscape is still developing, with few key players currently active in the region. Local pharmaceutical companies are exploring opportunities to introduce OIC treatments, while international players are assessing market entry strategies. The increasing focus on improving healthcare access and regulatory frameworks is expected to create opportunities for growth in the MEA region.

## Competitive Benchmarking

The Opioid Induced Constipation Drug Market is currently characterized by a complex interplay of competitive dynamics, driven by increasing awareness of opioid-induced side effects and a growing patient population requiring effective management solutions. Key players such as Boehringer Ingelheim (Germany), Takeda Pharmaceutical Company Limited (Japan), and AstraZeneca (United Kingdom) are strategically positioned to leverage their extensive research capabilities and established market presence. These companies focus on innovation and partnerships to enhance their product offerings, thereby shaping a competitive environment that emphasizes efficacy and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Pfizer Inc. (United States) and Salix Pharmaceuticals (United States) suggests a trend towards consolidation, as these firms seek to enhance their competitive edge through strategic collaborations and acquisitions. In August 2025, Boehringer Ingelheim (Germany) announced a partnership with a leading biotechnology firm to develop a novel formulation aimed at improving the efficacy of existing opioid-induced constipation treatments. This strategic move is likely to bolster Boehringer's portfolio and enhance its competitive positioning in a market that increasingly values innovative solutions. The collaboration underscores the importance of leveraging external expertise to accelerate product development cycles. In September 2025, Takeda Pharmaceutical Company Limited (Japan) launched a new digital health initiative aimed at improving patient adherence to opioid-induced constipation therapies. This initiative, which integrates mobile health technologies, reflects Takeda's commitment to enhancing patient outcomes through digital transformation. By focusing on patient engagement, Takeda appears to be positioning itself as a leader in the integration of technology within therapeutic management, potentially setting a new standard in the industry. AstraZeneca (United Kingdom) made headlines in July 2025 by acquiring a small biotech firm specializing in gut health. This acquisition is indicative of AstraZeneca's strategy to diversify its portfolio and strengthen its capabilities in addressing gastrointestinal disorders associated with opioid use. The move not only enhances AstraZeneca's product pipeline but also signals a broader trend of major pharmaceutical companies seeking to expand their therapeutic areas through targeted acquisitions. As of October 2025, the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of [artificial intelligence](https://www.marketresearchfuture.com/reports/artificial-intelligence-market-1139) in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, it seems that competitive differentiation will likely evolve from traditional price-based competition to a focus on technological advancements, innovative therapies, and robust supply chain management, thereby reshaping the market dynamics in the Opioid Induced Constipation Drug Market sector.

## Recent News & Developments

- **Q2 2024: Bausch Health Announces FDA Approval of New Formulation of RELISTOR® (methylnaltrexone bromide) Tablets for Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain** Bausch Health received FDA approval for a new formulation of RELISTOR® tablets, expanding treatment options for adults suffering from opioid-induced constipation related to chronic non-cancer pain.
- **Q1 2024: Daiichi Sankyo and Takeda Announce Strategic Partnership to Co-Develop and Commercialize Novel Opioid-Induced Constipation Therapy in Japan** Daiichi Sankyo and Takeda entered a strategic partnership to co-develop and commercialize a new therapy targeting opioid-induced constipation, aiming to address unmet needs in the Japanese market.
- **Q2 2024: AstraZeneca Receives European Commission Approval for MOVENTIG® (naloxegol) for Expanded Indication in Opioid-Induced Constipation** AstraZeneca secured European Commission approval for an expanded indication of MOVENTIG® (naloxegol), allowing broader use in patients with opioid-induced constipation across Europe.
- **Q3 2024: BioDelivery Sciences International Appoints New CEO to Lead Expansion in Opioid-Induced Constipation Drug Portfolio** BioDelivery Sciences International appointed a new CEO to drive the company's growth strategy, with a focus on expanding its opioid-induced constipation drug portfolio.
- **Q2 2024: Shionogi Launches New Opioid-Induced Constipation Drug in Japan** Shionogi launched a new prescription drug for opioid-induced constipation in Japan, marking its entry into the growing [gastrointestinal therapeutics](https://www.marketresearchfuture.com/reports/gastrointestinal-therapeutics-market-66833) market.
- **Q1 2025: Salix Pharmaceuticals Opens New Manufacturing Facility to Increase Production of OIC Therapies** Salix Pharmaceuticals opened a new manufacturing facility dedicated to increasing production capacity for its opioid-induced constipation therapies.
- **Q2 2025: Theravance Biopharma Announces Positive Phase 3 Results for TD-1211 in Opioid-Induced Constipation** Theravance Biopharma announced positive Phase 3 clinical trial results for TD-1211, a novel treatment for opioid-induced constipation, supporting future regulatory submissions.
- **Q1 2024: Nektar Therapeutics and Eli Lilly Enter Collaboration to Develop Next-Generation OIC Treatments** Nektar Therapeutics and Eli Lilly formed a collaboration to develop next-generation treatments for opioid-induced constipation, combining their expertise in pain and gastrointestinal disorders.
- **Q3 2024: Pfizer Sells Rights to OIC Drug to Specialty Pharma Firm** Pfizer sold the rights to one of its opioid-induced constipation drugs to a specialty pharmaceutical company, streamlining its portfolio and focusing on core therapeutic areas.
- **Q2 2025: Takeda Secures Regulatory Approval for New OIC Drug in Europe** Takeda received regulatory approval in Europe for a new opioid-induced constipation drug, expanding its gastrointestinal product offerings in the region.
- **Q1 2025: Mallinckrodt Announces $100 Million Investment to Expand OIC Drug Research and Development** Mallinckrodt announced a $100 million investment to expand research and development efforts focused on new therapies for opioid-induced constipation.
- **Q4 2024: Progenics Pharmaceuticals Receives FDA Fast Track Designation for OIC Drug Candidate** Progenics Pharmaceuticals received FDA Fast Track designation for its investigational drug targeting opioid-induced constipation, expediting the development and review process.

## Report Scope

| MARKET SIZE 2024 | 1.897(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.995(USD Billion) |
| MARKET SIZE 2035 | 3.307(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.18% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Boehringer Ingelheim (DE), Takeda Pharmaceutical Company Limited (JP), AstraZeneca (GB), Mallinckrodt Pharmaceuticals (IE), Pfizer Inc. (US), Sorrento Therapeutics (US), Salix Pharmaceuticals (US), NantKwest (US) |
| Segments Covered | Opioid Type, Drug Class, Route of Administration, Indication, Regional |
| Key Market Opportunities | Emerging therapies targeting opioid-induced constipation enhance patient compliance and address unmet medical needs. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in the Opioid Induced Constipation Drug Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Opioid Induced Constipation Drug Market in 2035?**
A: The projected market valuation for the Opioid Induced Constipation Drug Market in 2035 is 3.307 USD Billion.

**Q: What was the market valuation for the Opioid Induced Constipation Drug Market in 2024?**
A: The market valuation for the Opioid Induced Constipation Drug Market in 2024 was 1.897 USD Billion.

**Q: What is the expected CAGR for the Opioid Induced Constipation Drug Market from 2025 to 2035?**
A: The expected CAGR for the Opioid Induced Constipation Drug Market during the forecast period 2025 - 2035 is 5.18%.

**Q: Which companies are key players in the Opioid Induced Constipation Drug Market?**
A: Key players in the market include Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, AstraZeneca, Mallinckrodt Pharmaceuticals, Pfizer Inc., Sorrento Therapeutics, Salix Pharmaceuticals, and NantKwest.

**Q: What are the main drug classes in the Opioid Induced Constipation Drug Market?**
A: The main drug classes include Peripherally Acting Opioid Receptor Antagonists, Peripherally Acting Non-Opioid Receptor Agonists, Centrally Acting Laxatives, and Osmotic Laxatives.

**Q: How much is the Opioid-Induced Constipation segment valued at in 2024?**
A: The Opioid-Induced Constipation segment was valued at 1.2 USD Billion in 2024.

**Q: What is the valuation of the Antagonists segment in the Opioid Induced Constipation Drug Market?**
A: The Antagonists segment is valued at 0.38 USD Billion in 2024 and is projected to reach 0.654 USD Billion by 2035.

**Q: What routes of administration are available for drugs treating Opioid Induced Constipation?**
A: Available routes of administration include Oral, Rectal, and Intravenous.

**Q: What is the projected growth for the Peripherally Acting Opioid Receptor Antagonists segment by 2035?**
A: The Peripherally Acting Opioid Receptor Antagonists segment is projected to grow from 0.759 USD Billion in 2024 to 1.327 USD Billion by 2035.

**Q: How does the market for Non-Opioid-Induced Constipation compare to Opioid-Induced Constipation?**
A: The Non-Opioid-Induced Constipation segment was valued at 0.697 USD Billion in 2024, compared to 1.2 USD Billion for Opioid-Induced Constipation.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/opioid-induced-constipation-drug-market-33909*